Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine

Internal Medicine

Volumn 50, Issue 7, 2011, Pages 699-705

  Honda, Miwako ^a   Ishisaka, Michiyo ^a   Ishizuka, Naoki ^a   Kimura, Satoshi ^b   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b TOKYO TEISHIN HOSPITAL   (Japan)

Author keywords

Abacavir; Antiretroviral treatment; Atazanavir; Efavirenz; HIV; Lamivudine

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTILIPEMIC AGENT; ATAZANAVIR; EFAVIRENZ; RITONAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSOMNIA; JAPANESE; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; SIDE EFFECT; SKIN IRRITATION; SUICIDAL IDEATION; TREATMENT RESPONSE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; BILIRUBIN; CHOLESTEROL; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; JAPAN; LAMIVUDINE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; TREATMENT OUTCOME;

EID: 79953764766     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4572     Document Type: Article

References (29)

1. Lapphra K, Vanprapar N, Chearskul S, et al. Efficacy and tolerability of nevirapine-versus efavirenz-containing regimens in HIVinfected Thai Children. Int J Infect Dis 12: e33-e38, 2008.
2. Laureillard D, Prak N, Fernandez M, et al. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. HIV Med 9: 514-518, 2008.
3. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 19: 185-192, 2005.
4. Côté HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346: 811-820, 2002.
5. Chowers M, Gottesman BS, Leibovici L, Schapiro JM, Paul M. Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 29: 779-786, 2010.
6. Maggiolo F, Roat E, Pinti M, et al. Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatmentnaive patients. Antivir Ther 15: 51-59, 2010.
7. Tanuma J, Gatanaga H, Oka S, et al. Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. Clin Infect Dis 37: e109-e111, 2003.
8. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359: 727-732, 2002.
9. Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 60: 599-604, 2007.
10. Park WB, Choe PG, Song KH, et al. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 48: 365-367, 2009.
11. Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 9: 545-559, 2010.
12. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010 Feb 19 (Epub), DOI: 10.1097/QAI.0b013 e3181d05579
13. United States Department of Health and Human Services. DHHS Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, May 2006.
14. Gatanaga H, Tachikawa N, Kikuchi Y. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 22: 744-748, 2006.
15. Friis-Møller Nina, Reiss P, El-Sadr W, et al; D:A:D Study Group. Exposure to PI and NNRTI and risk of myocardial infarction: Results from the D:A:D Study, 13th conference on retrovirus and opportunistic infections. 2006 abstract 144.
16. Sabin CA, Worm SW, Weber R, et al; D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426, 2008.
17. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treatment Reports 69: 1375-1381, 1985.
18. Gallant JE, Rodriguez AE, Weinberg WG, et al. ESS30009 Study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naïve subjects. J Infect Dis 192: 1921-1930, 2005.
19. Sax PE, Tierney C, Collier AC, et al. AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy. N Engl J Med 361: 2230-2240, 2009.
20. Smith KY, Patel P, Fine D, et al. HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23: 1547-1556, 2009.
21. BULLETIN NIAID Modifies HIV Antiretroviral treatment study combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naïve individuals. http://www.niaid. nih.gov/news/newsreleases/2008/Pages/actg5202bulletin.aspx (accessed on July 15 2010).
22. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 43: 714-721, 2005.
23. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz and protease inhibitor-treated patients. HIV Clin Trials 6: 187-196, 2005.
24. van Luin M, Bannister WP, Mocroft A, et al; EuroSIDA Study Group. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther 14: 75-83, 2009.
25. Elzi L, Marzolini C, Furrer H, et al; Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 170: 57-65, 2010.
26. Torti C, Lapadula G, Antinori A, et al. Hyperbilirubinemia during Atazanavir Treatment in 2,404 Patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts. Infection 37: 244-249, 2009.
27. Josephson F, Andersson MC, Flamholc L, et al. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. Eur J Clin Pharmacol 66: 349-357, 2010.
28. United States Department of Health and Human Services. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents-December 1, 2009. http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL001419.pdf accessed on Jan 17 2011.
29. European AIDS Clinical Society. Guidelines of Clinical Management and Treatment of HIV infected adult in Europe. Version 5, 2009. http://www.europeanaidsclinicalsociety.org/guidelinespdf/ EACS-EuroGuidelines2009FullVersion.pdf accessed on Jan 17 2011.